Sign in

Private company

Ameritox

Logo: w:Ameritox, Public domain, via Wikimedia Commons3

American urine drug monitoring company

Ameritox was a company that provided physicians with urine drug monitoring and reporting services. Headquartered in Baltimore, Maryland, the company also had a CLIA-certified laboratory in Greensboro, North Carolina. Ameritox offered urine drug testing and reporting services to help physicians determine if their chronic pain patients are taking their pain medications correctly.2 Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

See how the biggest companies compare on our leaderboards

Ameritox was a company that provided physicians with urine drug monitoring and reporting services. Headquartered in Baltimore, Maryland, the company also had a CLIA-certified laboratory in Greensboro, North Carolina.2

The story

Ameritox Ltd. was founded in 1996 in Midland, Texas as Universal Toxicology Laboratories (UTL), a federally certified drug testing facility and medical examiner toxicology laboratory.

UTL identified a growing need for a more detailed way of monitoring the use of long-term pain medications used by patients. The company became Ameritox Ltd. in 2003. Today, Ameritox claims to be the nation's largest provider of pain medication monitoring solutions for physicians.

In 2018 Ameritox sold is book of business, auctioned equipment and other assets, and ceased to operate.

From Wikipedia’s article on Ameritox, shared under CC BY-SA 4.0.4

Products and brands

Products

Rx Guardian CD

Rx Guardian CD SM is now part of the Rx Guardian SM process. Rx Guardian CD SM features a unique reference database supported by a proprietary normalization algorithm. Patients’ normalized results are compared against the reference database, giving added confidence in assessing whether patients are taking their medications correctly.

Rx Guardian Insight Report

In 2012, Ameritox launched the Rx Guardian INSIGHT Report, which, according to a press release, "provides a concise summary of the most important elements of a patient's medication monitoring results. It also helps clinicians assess a patient's medication adherence over time by showing a chronology of previous Rx Guardian CD(SM) standard scores."

Research

Ameritox's clinical research program investigates topics related to managing patients on chronic opioid therapy. Studies include:

Patterns of Drug Use in the Older Chronic Pain Population (2012)

This poster was presented at the American Pain Society's annual meeting and showed "a significant rate of potential non-adherence in the older

Read the full text

population, supporting the need for routine urine drug monitoring in older adults in order to improve clinical decision making and enhance patient safety."

Healthcare costs and nonadherence among chronic opioid users (2011)

This study assessed the health economic burden of chronic opioid users and determined whether potential opioid regimen nonadherence is associated with increased healthcare costs. The study concludes that patients on chronic opioid therapy who were likely to be nonadherent to their prescription regimens, according to urine drug monitoring results, had significantly higher overall healthcare costs than patients who are likely adherent to their prescription regimen.

High Rates of Inappropriate Drug Use in the Chronic Pain Population (2009)

Ameritox and the Jefferson School of Population Health at Thomas Jefferson University conducted a national study to determine the rates of inappropriate use, and likely abuse, misuse and diversion of opioids among chronic pain patients, as measured by urine drug testing in the clinical setting. The results showed that 75% of patients in the study may not have been taking their pain medication consistent with their prescribed regimen.

From Wikipedia’s article on Ameritox, shared under CC BY-SA 4.0.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4